MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 30 - per page Next page
Order by
Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
Therapeutic method to treat prostate carcinomas by administration of cellular PAcP protein. More
This antibody is specific for the TCR CD3 epsilon chain and can also be used to identify this subunit in immunoprecipitation and immunoblotting applications More
Recently characterized MUC17 gene highly specific for pancreatic cancer. More
Acetaminophen-protein Adduct Dipstick: rapid, sensitive and specific diagnostic device for point-of-care determination of acetaminophen toxicity More
Diagnostic and potential therapeutic applications for mucin gene 4 (MUC4). More
Monoclonal antibody for a novel HIV protein with potential diagnostic, prognostic, and therapeutic uses. More
Antibodies generated in mouse lymphoma cells used to recognize human breast cancer. The antibodies in their current and modified forms can be used in the diagnosis, prognosis, and subsequent treatment of certain human breast cancers. Diagnosis of... More
The technology describes the humanization of a murine anti-carcinoma antibody CC49 which has been shown to react with Tumor Associated Glycoprotein 72 (TAG-72), an antigen which is expressed on human breast, ovarian, colorectal, and other carcinomas. More
Displaying 1..10 of 30 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us